It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @thelancet.com Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered www.thelancet.com/pdfs/journal...

This population-based study on the NCCN resectability stages of pancreatic adenocarcinoma indicates that the rate of LAPC was lower than reported in literature, whereas the rate of PRPC is higher

Published in @bjsurgery.bsky.social, unique nationwide 🇳🇱 data @dpcgofficial.bsky.social on #NCCN resectability staging of #PancreaticCancer at diagnosis: 🧷 23% PRPC 🧷 8% BRPC 🧷 11% LAPC 🧷 58% M1 … including stratification for tumour location. 👉 academic.oup.com/bjs/article/...

HPB Journal Highlight ⭐️Ishida et al. Global survey shows big variation in how surgeons manage neck of pancreas cancers, especially with vascular involvement. Highlights the need for future studies & clearer guidelines! 🔗https://tinyurl.com/3myun89t 📊🌎 #PancreaticCancer #HPBSurgery

Distribution of the NCCN stages of #PancreaticCancer ? 16,412 pts (2017-2022) 🇳🇱 👉23% primary resectable 👉 8% borderline resectable 👉 11% locally advanced 👉 58% metastatic ⏩️ academic.oup.com/bjs/article/11…

Published in #BJC, our 🌎 study with 935 localized #pancreaticancer patients after resection, comparing preoperative FFX vs GnP: 📎FFX vs GnP not associated with OS (p=0.17) 📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology 🚨Pragmatic RCT #chemosensitivitymarkers🔍 👉 www.nature.com/articles/s41...

Immensely honored to receive a Honorary Fellowship with #ASA #American #Surgical #Association #AnnalsOfSurgery in #SanDiego

Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030. A recent Seminar discusses the need for novel therapies & future directions for research: tinyurl.com/ywue2nfs

Published in @thelancet.bsky.social, our review on #PancreaticCancer 📎Epidemiology🌎 📎Pathogenesis🔬 📎Risk factors & surveillance🕵️ 📎Diagnostics🩺 📎Treatment💊 📎Future directions🔍 … by AA Javed, A Oba, T Seufferlein, JW Wilmink, @basgrootkoerkamp.bsky.social & @marcbesselink.bsky.social.

Congrats to #AnoukEmmen and @tfstoop.bsky.social for excellent presentations in the #PresidentialSession #AHPBA2025 AHPBA Miami 🇺🇸: #DIPLOMA2 RCT🇪🇺 robot/lap 🤖 vs open Whipple and #PREOPANC4🇳🇱 implementation of surgery for locally advanced #PancreaticCancer for @dpcgofficial.bsky.social and #EMIPS

Published in #hpbjournal, 🌎 survey on surgical management of pancreatic neck/body cancer with venous involvement: 📝222 surgeons, 49 countries, 6 continents 📍Heterogeneity in surgical management➡️particularly when ⬆️ venous involvement ⚠️ Need for research 🔍 @eahpba.bsky.social @ihpba.bsky.social

In JNCCN our nationwide study on quality of life in patients with locally advanced PDAC 🇳🇱 ⭐️ QoL remains stable over time, regardless of receiving treatment (89%) 😱 Symptoms significantly deteriorate and deserve attention ➡️ Use in shared decision making @dpcgofficial.bsky.social

In #BMC Cancer, #PREOPANC4 protocol to improve #LAPC care in 🇳🇱 @dpcgofficial.bsky.social with help of 4 international experts🇩🇪🇺🇸: 📎Multidisciplinary & surgical training program 📎Structured induction therapy, response evaluation & selection for surgery 📎National expertpanel 📎Patient-centered care

Looking back at an incredible #ALPS2025 meeting and delighted to have been awarded the Best Mini-Oral Presentation for our cost-analysis of robot vs open Whipple! Many thanks to the @amsterdamumc.bsky.social HPB-team @MichielFrancken @marcbesselink.bsky.social #roboticsurgery #pancreas

Preoperative stereotactic radiotherapy to prevent pancreatic fistula in high-risk patients undergoing pancreatoduodenectomy (FIBROPANC): prospective multicentre phase II single-arm trial ➡️ doi.org/10.1093/bjs/...

Can prophylactic #Radiotherapy #SBRT in non-PDAC #pancreatoduodenectomy prevent fistula POPF? 🔑 “it works but doesn’t help” ▶️#FIBROPANC published today @bjsurgery.bsky.social @dpcgofficial.bsky.social @eahpba.bsky.social @ihpba.bsky.social academic.oup.com/bjs/article/...

In JAMA Oncology our 🌎 @eahpba.bsky.social study on adjuvant chemo (AT) in 742 resected localized #PDAC patients following NAT #FFX (40 centers): 📌OS ⬆️ by AT; … only with multi-agent AT ⚠️ 📌Possibly less effect of AT if >=8c NAT FFX, RECIST response, ypN0 & head tumor 📣 📯RCT🟰🔑

PVR 1-2 vs 3-4 during pancreatoduodenectomy for resectable #PDAC with venous involvement? In Annals of Surgery, our observational study with 357 patients from 🇸🇪🇯🇵🇳🇱🇺🇸: 📌PVR type NOT associated with OS, locoregional recurrence & major morbidity ➡️ surgeon’s personal preference

Neoadjuvant chemotherapy for left 👈 sided resectable #PDAC 🪡 72% of US received adjuvant 💉 NAT had better OS (53 🆚 37 months) 🤏 Tumor size and 🧪 elevated CA19.9 correlates with benefits of NAT And now… time for RCT! 💪 #HPBSky www.annalsofoncology.org/article/S092...

NAT for left-sided RPC? In Annals of Oncology our 🌎 observational study on #NAT vs #US in 2282 patients with resected left-sided #RPC (76 centers): 📌OS⬆️after NAT vs US … 5y OS 47% vs 35% 📌NAT effect⬆️in large tumors & higher CA19.9 at diagnosis 🔑🟰ABC-approach 📯RCT See full text below 👇

Perioperative therapy for #Pancreas Cancer ⭐️ A stellar lecture by the great Matthew H Katz 🇺🇸 @mdanderson.bsky.social ⭐️ All you need to know, and future perspectives in the eyes of a true pioneer of neoadjuvant chemo #HPBSky #SurgSky #MedSky youtube.com/watch?v=kIlH...

2025 Multi-Societal #European #Guideline on #PancreaticCancer ✅ Meeting with our 39 amazing Research leads to discuss group progress and any issues ▶️ 30 Societies ▶️ 13 Working groups ▶️ Focus on knowledge gaps @eahpba.bsky.social Laura Leeuwenburgh, Magdalena Holze, Elena Rangelova